loading page

Decitabine combined regimen in the therapy of Blastic plasmacytoid dendritic cell neoplasm: case report
  • +2
  • Jun Guan,
  • Ying Zhou,
  • xia Mao,
  • Liang Zou,
  • Hui Cheng
Jun Guan
Wuhan No 1 Hospital

Corresponding Author:[email protected]

Author Profile
Ying Zhou
Wuhan No 1 Hospital
Author Profile
xia Mao
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Author Profile
Liang Zou
Wuhan No 1 Hospital
Author Profile
Hui Cheng
Wuhan No 1 Hospital
Author Profile


We enrolled a patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) . We have found that TET2, KRAS and BRAF may be involved in the development of the disease, and the combination therapy of Decitabine (DAC) and Arsenic acid (ASO) may be effective for BPDCN harboring the TET2 mutations.
01 Dec 2021Submitted to Clinical Case Reports
02 Dec 2021Assigned to Editor
02 Dec 2021Submission Checks Completed
12 Dec 2021Reviewer(s) Assigned
02 Jan 2022Review(s) Completed, Editorial Evaluation Pending
03 Jan 2022Editorial Decision: Revise Minor